Mesoblast (MESO) Projected to Post Quarterly Earnings on Thursday

Mesoblast (NASDAQ:MESO) is projected to issue its quarterly earnings data on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $2.39 million for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Mesoblast Trading Down 1.1 %

Shares of NASDAQ:MESO opened at $16.05 on Wednesday. The firm’s 50 day moving average price is $17.98 and its 200-day moving average price is $11.98. Mesoblast has a twelve month low of $1.91 and a twelve month high of $22.00. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on MESO shares. Piper Sandler restated an “overweight” rating and set a $24.00 target price (up previously from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. Jefferies Financial Group lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. Finally, Cantor Fitzgerald raised shares of Mesoblast to a “strong-buy” rating in a report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Mesoblast presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.